Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer

NCT02982395 is registered in ClinicalTrials.gov with Samyang Biopharmaceuticals Corporation as lead sponsor.

NCT NCT02982395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer
Lead sponsor
Samyang Biopharmaceuticals Corporation
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2017
Completion date
August 31, 2018
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non muscle invasive bladder cancer